Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.
Journal: Journal of medicinal chemistry
Published: May 27, 2026
Enabling faster and greener peptide purification in discovery chemistry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: July 21, 2025
Recurrent Wernicke's encephalopathy in pregnancy: A case report.
Journal: Nutritional neuroscience
Published: December 23, 2017
The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh2 antagonists.
Journal: Bioorganic & medicinal chemistry letters
Published: May 26, 2017
Bilateral external and internal pudendal veins embolization treatment for venogenic erectile dysfunction.
Journal: Radiology case reports
Published: August 30, 2016
Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
Journal: Bioorganic & medicinal chemistry letters
Published: February 25, 2014
Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties.
Journal: Bioorganic & medicinal chemistry letters
Published: October 18, 2013
SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist.
Journal: Bioorganic & medicinal chemistry letters
Published: November 16, 2011
Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: October 21, 2011
Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes.
Journal: ACS medicinal chemistry letters
Published: October 19, 2011
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.
Journal: ACS medicinal chemistry letters
Published: October 15, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026